Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer

BACKGROUND: Lorlatinib is a potent, third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) designed to penetrate the blood–brain barrier. OBJECTIVE: We report the cumulative incidence of central nervous system (CNS) and non-CNS progression with lorlatinib in patients with ALK-positive non-small-c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Target Oncol
Hauptverfasser: Bauer, Todd M., Shaw, Alice T., Johnson, Melissa L., Navarro, Alejandro, Gainor, Justin F., Thurm, Holger, Pithavala, Yazdi K., Abbattista, Antonello, Peltz, Gerson, Felip, Enriqueta
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer International Publishing 2020
Schlagworte:
Original Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7028836/
https://ncbi.nlm.nih.gov/pubmed/32060867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-020-00702-4
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge